100 related articles for article (PubMed ID: 16647466)
1. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
Stracke S; Ramudo L; Keller F; Henne-Bruns D; Mayer JM
Transplant Proc; 2006 Apr; 38(3):766-70. PubMed ID: 16647466
[TBL] [Abstract][Full Text] [Related]
2. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Tuncyurek P; Mayer JM; Klug F; Dillmann S; Henne-Bruns D; Keller F; Stracke S
Eur Surg Res; 2007; 39(6):380-7. PubMed ID: 17700025
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.
Shen Y; Wang X; Xia W; Wang C; Cai M; Xie H; Zhou L; Zheng S
Transplant Proc; 2008 Jun; 40(5):1727-33. PubMed ID: 18589181
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.
Azzola A; Havryk A; Chhajed P; Hostettler K; Black J; Johnson P; Roth M; Glanville A; Tamm M
Transplantation; 2004 Jan; 77(2):275-80. PubMed ID: 14742993
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
Voisard R; Geçgüner L; Baur R; Herter T; Hombach V
Int J Cardiol; 2005 Jul; 102(3):435-42. PubMed ID: 16004888
[TBL] [Abstract][Full Text] [Related]
6. Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models.
Voisard R; Viola S; Kaspar V; Weber CM; von Müller L; Baur R; Gastrock-Balitsch I; Hombach V
BMC Cardiovasc Disord; 2005 May; 5(1):9. PubMed ID: 15890069
[TBL] [Abstract][Full Text] [Related]
7. [Toxic effect of immunosuppression agent Everolimus on insuloma cells and pancreatic islets of SD rat].
Jin X; Cong C; Yuan Y; Mai G; Wei LL; Chen YN; Cheng JQ; Lu YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 41(1):68-72. PubMed ID: 20369473
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.
Hostettler KE; Halter JP; Gerull S; Lardinois D; Savic S; Roth M; Tamm M
Eur Respir J; 2014 Jan; 43(1):221-32. PubMed ID: 23645405
[TBL] [Abstract][Full Text] [Related]
9. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
Lin J; Wang YH; Zhang YH; Tian Y
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):388-91. PubMed ID: 22490898
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.
Machka C; Lange S; Werner J; Wacke R; Killian D; Knueppel A; Knuebel G; Vogel H; Lindner I; Roolf C; Murua Escobar H; Junghanss C
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1301-6. PubMed ID: 24923538
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.
Liu C; Schreiter T; Frilling A; Dahmen U; Broelsch CE; Gerken G; Treichel U
World J Gastroenterol; 2005 Dec; 11(48):7602-5. PubMed ID: 16437685
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.
Koehl GE; Wagner F; Stoeltzing O; Lang SA; Steinbauer M; Schlitt HJ; Geissler EK
Transplantation; 2007 Mar; 83(5):607-14. PubMed ID: 17353782
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.
Hauser IA; Renders L; Radeke HH; Sterzel RB; Goppelt-Struebe M
Nephrol Dial Transplant; 1999 Jan; 14(1):58-63. PubMed ID: 10052478
[TBL] [Abstract][Full Text] [Related]
14. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
[TBL] [Abstract][Full Text] [Related]
15. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
Annemans L; Lemkuhl H; Tenderich G; Schulz U; Yang XL; Ricci JF; Hetzer R
Transplant Proc; 2007 Dec; 39(10):3306-12. PubMed ID: 18089377
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts.
Heinz C; Hudde T; Heise K; Steuhl KP
Graefes Arch Clin Exp Ophthalmol; 2002 May; 240(5):408-14. PubMed ID: 12073065
[TBL] [Abstract][Full Text] [Related]
18. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
Billing H; Burmeister G; Plotnicki L; Ahlenstiel T; Fichtner A; Sander A; Höcker B; Tönshoff B; Pape L
Transpl Int; 2013 Sep; 26(9):903-9. PubMed ID: 23865768
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
